Combining the alpha-blocker alfuzosin SR (Uroxatral) with the phosphodiesterase type-5 inhibitor sildenafil citrate (Viagra) appears to produce a greater therapeutic benefit in men with lower urinary tract symptoms than either drug alone, researchers said yesterday.

Robert C. Flanigan, MD, was named the new secretary of AUA during the association's business meeting yesterday. He is professor and chair of urology at the Loyola University Health System, Maywood, IL.

Intraprostatic injection of botulinum toxin type A (Botox) is a safe and effective treatment in patients with symptomatic BPH that results in improvements in symptoms and quality of life that may persist for up to 1 year, researchers from Taiwan said.

Despite media images depicting middle-aged and older men embracing the use of phosphodiesterase type-5 inhibitors to correct erectile dysfunction, actual interest and usage in this population is unknown.

Once-a-day tadalafil (Cialis) at dosages ranging from 5 mg to 20 mg produces measurable benefits in men with BPH and lower urinary tract symptoms, according to a multicenter study presented here yesterday.

Cook Urological introduced on Tuesday a new biomaterial known as Surgisis ES for the treatment of Peyronie's disease. Surgisis ES is a natural biomaterial that provides a graft that is strong, easy to handle, easy to use, and biocompatible, the company said. It supports the growth of new fully vascularized host tissue in the penis.

Two separate studies have found that men and women dealing with infertility suffer from depression and anxiety at a greater rate than the general population.

Long-term survival of inflatable penile prostheses (IPPs) that have been in use over the past 2 decades is excellent, and the reliability of those devices appears even more promising for the enhanced models that have become more recently available, said Steven K. Wilson, MD.

Stimulation of the pudendal nerve may be an alternative to sacral neurostimulation (SNS) in the treatment of urinary voiding dysfunction. Two studies presented yesterday indicate that pudendal neurostimulation (PNS) is effective in patients who do not respond to SNS.